FiercePharmaOriginal article
{"a":[{"_":"Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path","$":{"href":"/pharma/unapproved-us-decades-levosimendan-stumbles-phase-3-tenax-eyes-narrow-fda-path","hreflang":"en"}}]}
Phase 3negativelevosimendanNegative
AI Analysis
Summary
Levosimendag, a cardiovascular drug seeking FDA approval after nearly three decades, has failed to achieve a decisive clinical win in phase 3 testing. Tenax Therapeutics is exploring a narrow regulatory pathway for potential U.S. market entry.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial failed to achieve decisive clinical win
Importance:6/10
Sentiment:
-0.70
Phase 3 failureFDA approvalcardiovascular drugregulatory pathway
Read the original article
Published by FiercePharma on August 10, 2026 4:14 PM